Biomarin Pharmaceutical Inc
F:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomarin Pharmaceutical Inc
F:BM8
|
US |
|
Equitable Holdings Inc
NYSE:EQH
|
US |
|
F
|
Ford Motor Co
XETRA:FMC1
|
US |
|
C
|
Colgate-Palmolive Co
XHAM:CPA
|
US |
|
C
|
Compugen Ltd
XBER:CW9
|
IL |
|
ING Groep NV
AEX:INGA
|
NL |
|
Richards Packaging Income Fund
OTC:RPKIF
|
CA |
|
Bayer AG
XETRA:BAYN
|
DE |
|
M
|
Murata Manufacturing Co Ltd
XMUN:MUR1
|
JP |
|
Budweiser Brewing Company APAC Ltd
HKEX:1876
|
HK |
|
F
|
FirstEnergy Corp
LSE:0IPB
|
US |
|
Autozone Inc
NYSE:AZO
|
US |
|
T
|
Texas Instruments Inc
XBER:TII
|
US |
|
T
|
TAG Immobilien AG
OTC:TAGOF
|
DE |
Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms. The company sells mainly to hospitals, specialty pharmacies, and doctors who treat patients with these rare conditions. It earns money by selling these treatments, usually through highly specialized drug distribution channels and reimbursement from insurers and government health programs. Because its medicines target small patient groups, BioMarin depends on deep expertise in rare-disease research, regulatory approval, and patient support. What makes BioMarin different is its focus on a narrow set of hard-to-treat diseases where few other drug makers compete directly. It is part of the orphan-drug industry, where success comes from finding patients, proving strong clinical benefit, and building trusted relationships with specialists and payers. This gives the company a business model centered on specialized science and long-term treatment demand rather than broad-volume drug sales.
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms.
The company sells mainly to hospitals, specialty pharmacies, and doctors who treat patients with these rare conditions. It earns money by selling these treatments, usually through highly specialized drug distribution channels and reimbursement from insurers and government health programs. Because its medicines target small patient groups, BioMarin depends on deep expertise in rare-disease research, regulatory approval, and patient support.
What makes BioMarin different is its focus on a narrow set of hard-to-treat diseases where few other drug makers compete directly. It is part of the orphan-drug industry, where success comes from finding patients, proving strong clinical benefit, and building trusted relationships with specialists and payers. This gives the company a business model centered on specialized science and long-term treatment demand rather than broad-volume drug sales.
Amicus close: BioMarin closed the Amicus acquisition last week, adding Galafold, Pombiliti and Opfolda and lifting its 2026 revenue growth outlook to 20% at the midpoint.
Q1 revenue: First-quarter revenue was $766 million, helped by stronger patient demand in Enzyme Therapies and VOXZOGO, but partially offset by order timing and lower revenue from Roctavian, KUVAN and royalties.
VOXZOGO demand: New patient starts for VOXZOGO increased across all regions, with more than 20% year-over-year patient growth and more than half of new U.S. starts coming from children under age 2.
PALYNZIQ launch: BioMarin said the U.S. adolescent label expansion is off to an encouraging start, with meaningful enrollments and new patient starts under 18 expected to build over the next few quarters.
Guidance raised: Full-year 2026 total revenue guidance rose to $3.825 billion to $3.925 billion, while Enzyme Therapies guidance increased to $2.725 billion to $2.775 billion.
EPS outlook: Full-year non-GAAP diluted EPS guidance was updated to $4.85 to $5.05, with management saying Amicus will be slightly dilutive in 2026 but accretive in the first 12 months after close and substantially accretive in 2027.
Pipeline catalysts: BioMarin expects pivotal second-quarter readouts for VOXZOGO in hypochondroplasia and BMN 401 in ENPP1 deficiency, plus more updates on BMN 333 later in 2027.
